No Data
No Data
Express News | Citic Sec: Short-term view of the medical beauty industry focuses on track-exclusive products and item development, while the long-term perspective emphasizes platform strength.
MIRICOR: ANNUAL REPORT 2023/24
Hong Kong's pharmaceutical stocks rebounded today! After a deep adjustment from the beginning of the year until now, can they achieve a bottom-up rebound?
Since 2024, innovative drugs have received a variety of benefits from the policy combination. From multi-dimensional support for speeding up the registration and evaluation of innovative drugs, promoting multi-tiered innovation, and reasonable pricing of new drugs, the policy has moved from 'encouraging large-scale innovation' to 'encouraging high-quality innovation'.
BOC International: Continued prosperity of upstream medical beauty manufacturers opens up space for external expansion.
According to the research reports released by BOC International, the performance of leading medical and aesthetic companies is still maintaining good growth, and the average product price has not shown any price reduction pressure. The constantly enriched product matrix is expected to bring growth in the future.
Has the peak of summer medical beauty consumption been flattened out? Behind the market diversion, the performance of institutions may be further divided|Industry observation
Is the trend of flattening the peak of summer medical beauty significantly? Recently, Caixin reporters visited several medical beauty institutions that were supposed to be in the "peak sales period" and did not find a "booming" phenomenon.
Miricor Enterprises Reduces Loss in Fiscal Year 2024
No Data
No Data